Nanotherapeutics IN VIVO Reprogramming

About Us


Dr. Frederick S. Hagen
Chief Executive Officer

During his tenure at ZymoGenetics, Dr. Hagen experienced first-hand the development and maturation of a biotechnology company from startup through buyout by Novo Nordisk. Major accomplishments at ZymoGenetics include cloning and expression of the cDNA for Factor VII. This blood coagulation protein, NovoSeven®, has had sales of $15 billion over the life of the product until year end 2014 and is currently about a $1.5 billion-per-year product for Novo Nordisk. While at ZymoGenetics, Dr. Hagen spent a year at Novo Nordisk headquarters in Copenhagen, Denmark, during the development of NovoSeven®, where he gained experience in the operations of a large pharmaceutical company.

After ZymoGenetics, Dr. Hagen founded Icogenex biotechnology company. While CEO of Icogenex, he negotiated 9 contract projects with other pharma and biotech companies and Icogenex received funding on 19 grants from National Institutes of Health (NIH). Dr. Hagen has 21 issued patents and is an author on 34 peer-reviewed journal articles. Dr. Hagen received his Ph.D. from the University of Washington, completed his postdoctoral work at Harvard Medical School, and has 16 years of experience as CEO of Icogenex Corporation.

Dr. Andranik Andrew Aprikyan
Founder, Chief Scientific Officer (CSO), and Vice President

Dr. Aprikyan is a Co-Founder, Chief Scientific Officer, Vice President of Stemgenics, and the inventor of the Stemgenics nanoparticle reprogramming technology. Formerly he was a Research Assistant Professor at the School of Medicine Hematology/Oncology, University of Washington. Dr. Aprikyan’s 25 years of research and teaching experience mostly at the University of Washington School of Medicine first as a Senior Postdoctoral Fellow and then as faculty in the School of Medicine Hematology/Oncology set the stage for his recent discoveries.

For the last 15 years, his focus has been molecular biology, correction of pathological conditions triggered by various gene mutations, and therapeutic potential of human pluripotent stem cells, bone marrow stem/progenitor cells and more specialized cell types. This research and recent scientific discoveries led to the development of the Stemgenics nanoparticle reprogramming technology. Dr. Aprikyan has 25 published journal articles in peer-reviewed journals.

Scientific Advisors/Consultants

H. Joachim Deeg, MD

Dr. Deeg is a Professor of Medicine, University of Washington and a Member of Clinical Research Division, Fred Hutchinson Cancer Research Center (FHCRC). He has treated many cancer patients with stem cell therapy and successfully prosecuted a number of clinical protocols through FDA approval.

Carol Ware, Ph.D.

Dr. Ware is Professor of Comparative Medicine and Director of the Tom and Sue Ellison Stem Cell Core and Associate Director of the Institute of Stem Cell and Regenerative Medicine, University of Washington. Her research has focused on pluripotent stem cells for over 30 years and currently focuses on induction of pluripotency and the factors that control the maintenance of pluripotency.

Aravind Ramakrishnan, MD

Dr. Ramakrishnan is Assistant Member of the FHCR and Assistant Professor of Medicine at the University of Washington. Dr. Ramakrishnan is an expert on mature cell reprogramming into stem cells using lenti-viruses and episomal vectors.

Zaza Khuchua, Ph.D.

Dr. Khuchua is Associate Professor of Pediatrics/Molecular Cardiology, University of Cincinnati, OH. Dr. Khuchua is an established expert in cardiovascular biology and cardiac physiology.